Each month, the NATA scientific committee organises a one-hour interactive session led by top experts, featuring a hot topic related to clinical practice.
Registered participants can submit questions during the session.
Stefan D. ANKER
Professor of Cardiology & Metabolism, Charité – Universitätsmedizin Berlin
Professor of Tissue Homeostasis in Cardiology, Berlin Institute of Health (BIH)
Principal Investigator, German Centre for Cardiovascular Research (DZHK)
Toby RICHARDS MD FRCS FRACS DipPOM
Professor of Surgery, School of Health, Sport & Bioscience UEL
Hon. Professor Institute of Clinic Trials and Methodology UCL
Hon. Professor Department of Anaesthesia & Perioperative Medicine Monash University
Supported by an unrestricted educational grant from Pharmacosmos
Following our webinar on Heparin-induced thrombocytopenia (HIT), Prof. Gabor Erdoës has provided answers to several questions raised during the session, addressing important aspects of HIT diagnosis and management.
HIT antibodies usually disappear over weeks to months. The median time to a negative functional assay, which detects platelet-activating antibodies, is approximately 50 days, compared with 85 days for an immunoassay, which detects antibody binding. These are population estimates, and antibody persistence varies considerably between individuals.
For diagnosis, test as soon as HIT is clinically suspected; there is no need to wait after stopping heparin. Interpret an IgG-specific PF4/heparin immunoassay alongside clinical probability and, where indicated, a functional assay such as SRA or HIPA. Treatment should not be delayed while awaiting confirmation when clinical suspicion is sufficiently high. If the question is whether heparin can be used again for cardiac surgery, repeat testing should establish the current antibody status. Elapsed time alone is less reliable.
Yes, fondaparinux is a guideline-supported treatment option, although its use for HIT is generally off-label. It is particularly useful in clinically stable patients with adequate renal function. In critically ill patients, those with substantial bleeding risk, or those likely to require urgent procedures, a shorter-acting intravenous agent such as argatroban or bivalirudin is usually preferable. Fondaparinux is renally cleared and should generally be avoided when creatinine clearance is below 30 mL/min because of the risk of accumulation and bleeding.
I would avoid routine prophylactic platelet transfusion merely to correct the platelet count. However, HIT is not an absolute contraindication to platelet transfusion: clinically significant active bleeding or an urgent procedure with a high bleeding risk can justify transfusion. Life-threatening bleeding should not go untreated because of the HIT diagnosis.
In practice, I would assess whether thrombocytopenia is contributing to the bleeding and simultaneously investigate surgical bleeding, excessive anticoagulation, fibrinogen deficiency, and other coagulopathies. The aim is hemostasis rather than normalization of the platelet count. Any temporary interruption of anticoagulation requires frequent reassessment because HIT remains strongly prothrombotic.
Yes. Low-molecular-weight heparin (LMWH) can cause immune HIT, although the risk is substantially lower than with unfractionated heparin. Once HIT develops, switching from unfractionated heparin to LMWH is inappropriate because HIT antibodies commonly cross-react. Both forms of heparin must be discontinued, and a non-heparin anticoagulant must be used. The diagnostic and treatment principles are otherwise the same.
The decisive issue is the current platelet-activating antibody status, alongside bleeding risk, organ function, and the center’s experience. I would establish a joint plan with cardiac surgery, cardiac anesthesia, perfusion, hematology, and transfusion medicine:
If the functional assay is negative, intraoperative heparin for cardiopulmonary bypass, followed by protamine reversal, is supported, even if the immunoassay remains positive.
If the functional assay remains positive, bivalirudin during bypass is an established option in experienced centers. Alternatively, plasma exchange, with or without intravenous immunoglobulin (IVIG), can facilitate intraoperative heparin use.
After cardiac surgery, use a non-heparin anticoagulant when anticoagulation is required, particularly with active HIT or ongoing ECMO, and monitor for recurrent thrombocytopenia and thrombosis after any heparin re-exposure.
The 2026 ISTH guidance identifies bivalirudin as having the strongest supporting data, but no universally superior strategy exists. Bivalirudin requires a dedicated bypass protocol, including avoidance of stagnant blood in the circuit.
The existing bivalirudin infusion for ECMO cannot simply be assumed to provide adequate bypass anticoagulation. The lack of a reversal agent for bivalirudin also matters when planning hemostasis.
ASFA includes HIT-related plasma exchange as Category III, grade 2C: its optimal role is not established, and decisions should be individualized. This supports selected use rather than routine treatment of every patient with HIT.
Both albumin and plasma are acceptable replacement fluids. Plasma may be preferable immediately before cardiac surgery because it replaces coagulation factors and supplies immunoglobulins that may inhibit antibody-mediated platelet activation. Albumin-based exchange can reduce coagulation-factor levels. ASFA describes exchanges of approximately 1-1.5 total plasma volumes. There is no universally validated number of exchanges or timing schedule: published approaches range from one exchange immediately before surgery or intraoperatively before bypass to several exchanges over the preceding days. Timing should be coordinated with planned heparin exposure and, where available, functional testing. IVIG can complement antibody removal by inhibiting antibody-mediated platelet activation. If IVIG is combined with plasma exchange, it should generally be administered after the final planned exchange to avoid removing the infused immunoglobulin. Evidence remains largely observational. Neither an arbitrary number of exchanges nor a lower immunoassay value guarantees safe heparin re-exposure.